At Health Advances, we’re passionate about healthcare. We don’t just work with the industry, we’re part of the industry. Our leaders sit on boards. We’ve started companies and worked in business, scientific, technical, medical, and investment environments. The result is an unsurpassed level of industry understanding and knowledge that informs every project.
Sheela is a leader in Health Advances’ biopharma practice, helping companies maximize the value of their assets and build winning market positions.
Experienced in multiple therapeutic areas, she has particular expertise in metabolic and autoimmune diseases. Sheela brings a cross-sector lens to her biopharma clients, providing strategic advice on integrated solutions and convergent products.
Sheela joined Health Advances in 2005 with a background in corporate strategy and health care provider operations. Prior to Health Advances, Sheela worked at The Advisory Board where she managed client relationships and led research teams in areas related to hospital care delivery and new payment models. She also worked at Novartis Pharmaceuticals in the Cardiovascular Business Franchise.
Sheela earned a BA in human biology with university distinction and Phi Beta Kappa from Stanford University, and an MBA from the Harvard Business School.
Gary joined Health Advances in 2005 and leads the firm’s Precision Medicine Practice.
A noted writer and workshop leader in the field of companion diagnostics and precision medicine, his work focuses on commercialization strategy, indication prioritization, pricing and reimbursement strategy, system economics, and business development opportunities for both diagnostic and therapeutic clients.
Prior to joining Health Advances, Gary was a researcher at Brookhaven National Lab evaluating a proprietary line of synthetic growth factors. Gary also worked in the Cell & Tissue Technologies group at Becton Dickinson, the Exploratory Cancer Research group at OSI Pharmaceuticals, and most recently the Corporate Strategy group at Millennium Pharmaceuticals. Gary received his BSE degree in Biomedical Engineering from Duke University and his MS degree in Biomedical Engineering from Stony Brook University.
Tracy works with a wide variety of medical device clients ranging from small start-ups to some of the largest public companies in the industry.
She partners with clients to develop growth strategies for medtech products across sites of care including hospital and physician office, and has extensive experience in many therapeutic areas including neurology, ophthalmology, and cardiology.
Prior to joining Health Advances in 2006, Tracy worked at the Equinox Group where she advised pharmaceutical companies on the commercial outlook of developmental agents to support licensing and product development decisions. She also worked at Johnson & Johnson Health Care Systems on internal consulting projects for various Johnson & Johnson operating companies, including both medical device and pharmaceutical companies.
Tracy earned a BS in statistics from Lehigh University, and an MBA from the University of Michigan Ross School of Business with an emphasis in Corporate Strategy.
Vivek leads Health Advances’ San Francisco office and is focused on building Health Advances’ expertise in translational medicine through his work across therapeutics, diagnostics, and life science tools.
This broad exposure allows Vivek to leverage his scientific background to help companies across the spectrum of discovery, development, and commercialization of novel technologies. A core component of Vivek’s work is in opportunity identification, either for new platform technologies or for companies seeking to expand into new markets. Experienced in multiple therapeutic areas, he has particular expertise in immunology, oncology, ophthalmology, and orphan disease.
Prior to his work at Health Advances, Vivek earned his PhD in Molecular Cell Biology at Washington University in Saint Louis, studying G-protein regulation. While at WashU, Vivek founded the BioEntrepreneurship Core (BEC), a program designed to introduce life science students to the drug development process. BEC was a awarded a Kauffman Grant and has gone on to train many like-minded students.
Vivek received a BA in Biochemistry/Molecular Biology and an MA in Biotechnology from Boston University.
Kristen joined Health Advances in 2011 overseeing all finance responsibilities serving as Chief Financial Officer for 7 years.
Kristen came to Health Advances, after earning her CPA with Deloitte and with strong prior controllership experience at both large and small private contractors in the Boston area.
Now, as Health Advances Managing Director and Chief Operating Officer, Kristen brings over 20 years in managerial, operational and financial management. She oversees and directs the administrative functions and infrastructure necessary to deliver the highest quality product to our clients.
Kristen earned her BS in Accounting from Merrimack College.
Susan co-leads the Medtech Practice Group at Health Advances, where she has worked on over 200 project engagements, with a wide variety of clients ranging from small start-ups to some of the largest public companies in the industry.
Susan’s work with these companies has helped to optimize the value of products and technologies through extensive market evaluations, due diligence of M&A opportunities, and the development of strategies for sales and marketing efforts. She has extensive experience in the device sector, including women’s health, urology and critical care. Susan has published articles in a number of industry journals including a Medtech Insight article focusing on the value proposition for medtech products and is a previous MassMEDIC board member.
Prior to joining Health Advances in 2000, Susan worked at Interneuron Pharmaceuticals, Inc. in the areas of business development, marketing, and product management. Susan’s high technology experience also includes Molten Metal Technology, Inc. Susan earned her BA in General Science with a minor in Business and Managerial Economics from Brandeis University.
Donna joined Health Advances in 2005 and leads the firm’s Diagnostics and Life Science Tools Practice, a global practice which combines her consulting and scientific experience to provide results-oriented commercialization strategies for her clients.
Her work includes application and R&D prioritization, launch strategy, corporate strategy and portfolio optimization, deal diligence, international and domestic market analysis using both qualitative and quantitative approaches, and pricing and reimbursement strategies. Her clients offer products and services in precision medicine, point-of-care, mainstream clinical diagnostic, and life science tools and range from small diagnostics and tools start-ups to the largest public companies and non-profit institutions in the industry.
Prior to joining Health Advances, Donna worked as a scientist at One Cell Systems and Iquum developing diagnostics for oncology and infectious diseases. She received her Bachelor’s degree in Biology from the University of Illinois at Urbana-Champaign and her PhD in Immunology from the Sackler School of Biomedical Sciences at Tufts University.
Greg co-leads Health Advances’ Health IT and Digital Health practice, based on nearly 20 years of experience in strategy, management consulting, marketing, operations, and technology leadership.
A computer engineer and manager by training, Greg’s career has included software development and technical project management; strategic growth consulting to the Fortune 500 in biotech, high tech, and government; product management; B2B strategic marketing and communications; and senior operations leadership.
Prior to Health Advances, Greg held multiple senior executive roles at Arcadia.io, a healthcare data and software company dedicated to healthcare organizations achieving financial success in value-based care, working with health systems, providers, payers, and life science companies, including some of the largest, most complex, and influential health systems and health plans in the country. Greg founded and ran a Strategic Marketing team after an initial round of growth equity and drove company-wide business planning, performance improvement and measurement programs as the Strategic Operations leader. Earlier in his tenure, he was the product director for the core Arcadia Analytics platform and a principal consultant in Arcadia’s legacy consulting business. While at Arcadia, Greg also served as a subject matter expert to the Office of the National Coordinator for HIT on health information exchange (HIE) under the federal HIE, Regional Extension Center, and Beacon Community grant programs.
Greg began his career as a case team leader and technical project manager at Monitor Group (now part of Deloitte), serving clients in the biopharma, high tech, and government sectors.
Greg holds a Masters of Engineering Management degree from the Thayer School of Engineering at Dartmouth College, a collaborative program with the Tuck School of Business. He holds a BE and BA in Engineering and Computer Science, also from Dartmouth College.
Carrie joined Health Advances in 2007 and leads the firm’s Orphan Disease Practice. At Health Advances, Carrie works towards the advancement of novel therapeutics, drawing from experience across commercialization and development strategies and benchmarking, new product planning, and market assessment & forecasting.
Her clients have ranged from small start-ups and university technology transfer offices to the largest biopharmaceutical companies and private equity firms. With experience across multiple therapeutic areas, she is particularly interested in specialty markets including orphan, ophthalmology, metabolic, and respiratory diseases.
Prior to joining Health Advances, Carrie received her MS degree in organic chemistry from Massachusetts Institute of Technology, and she worked for several years as a medicinal chemist at Merck & Co., Inc. in Rahway, New Jersey where she developed her interests in drug discovery and development.
Carrie received a BA in chemistry from Williams College.
Balazs co-leads Health Advances’ Metabolic and Autoimmune Diseases Practice based on nearly 20 years of experience in the biopharma industry. He supports clients with a wide range of strategic issues, including indication assessment, portfolio strategy, commercialization as well as M&A and licensing support.
Balazs’ work enables his clients to formulate corporate and product strategies, make well-informed investment decisions, raise capital and form strategic partnerships.
He joined Health Advances after a successful career with biopharma companies ranging from industry leading biotechnology firms to small start-up operations. In roles of increasing responsibility, Balazs helped raise capital, executed high-value business development transactions, managed development and commercialization alliances, and built high-performing teams.
Balazs holds a Master of Science in Economics from Corvinus University in Budapest, Hungary as well as an MBA in Finance from the Wharton of School of Business at the University of Pennsylvania. He graduated with honors from both institutions.
Kristen Garner Amanti joined the Health Advances team in 2010 and is a leader in the Precision Medicine practice.
She has deep experience in commercialization strategy, business development opportunity assessment, deal diligence, international and domestic market assessment, corporate strategy, and is a seasoned workshop facilitator. She has content expertise in companion diagnostics, reproductive and prenatal health, rare disease, cancer screening, tumor genetics and oncology.
Prior to joining Health Advances, Kristen received her PhD in Cancer Pharmacology from Dartmouth College where her research focused on the development of novel targeted cancer therapeutics. She received her Masters degree in Cell and Molecular Biology and Bachelors degree in Biology from the University of Vermont.
Darcy has over 20 years of strategic healthcare consulting experience, having advised medical device, biopharma, and healthcare consumer clients in the areas of new product development, market access and commercialization strategies.
At Health Advances, Darcy partners with clients to create and capture the full value of their medical devices, supplies, and services in acute, ambulatory, long-term, and home settings globally. With expertise across multiple therapeutic areas, she has particular interest in wound care, surgical/acute/trauma wound hemostasis and closure, orthopedics, surgical devices and supplies, and other devices and equipment used in the hospital, outpatient centers or home. She has overseen several direct-to-consumer device projects. Darcy brings deep experience in market research techniques, especially the value of emerging methods, like Social Listening, as well as quantitative methods in pricing and trade-off analyses. She leads Health Advances Market Insights Group.
Prior to Health Advances, Darcy was a Principal in GfK’s Market Access Practice, co-leading the Medical Device Center of Excellence. In this role, Darcy led projects related to coding, coverage, reimbursement, and pricing strategies as well as the development of tactical materials to convey value for medical devices and prophylactic vaccines. She has extensive experience in primary and secondary market research to support evidence planning, value story development, pricing and forecasting. She has also held consulting roles with increasing responsibility at Abt Associates, Arthur D. Little and Decision Resources Group (DRG) Consulting. Darcy earned a BA in psychology from Bates College.
Peter has over 30 years of healthcare experience including corporate executive, principal investor and strategy consulting positions across diagnostics, life science research products, medical devices and biopharmaceuticals.
With an integrated view of technology commercialization, medical markets and corporate capability, Peter applies deep experience in advising clients on strategic decisions. He primarily focuses on Health Advances’ Diagnostics practice including core, specialty and point of care diagnostics.
From 2004 to 2018, Peter held executive leadership positions at Becton Dickinson, GE Healthcare and Ortho Clinical Diagnostics. In these roles he advised C-suite leadership and Boards of Directors, and led transformational licensing, partnership and M&A transactions. Notable transactions include the Ortho partnership with Quotient Biomedical, acquisition of Hyclone by General Electric, acquisition of Handylab at Becton Dickinson, and the point of care strategy and acquisition of assets for BD’s Veritor rapid diagnostics platform. Previously, he held positions as a Partner with Radius Ventures, as a consultant with The Wilkerson Group and Bain, and business development, marketing and sales positions with Schering-Plough, Genentech and Roche Laboratories, respectively.
Peter holds a Master of Science in Industrial Administration from the Tepper School at Carnegie Mellon University, and undergraduate degrees in Genetics and History from the University of California at Berkeley.
Kristine has over 15 years of Life Science industry experience that spans diagnostics, medical devices, and therapeutics. She has held positions in market planning, business analytics, marketing, and business development.
Most recently, Kristine spent four years at a small cap oncology molecular diagnostic company where she led marketing and planning. During that time, she helped to take the company public, led the portfolio management and corporate planning efforts, and developed the commercial plan for their launch. She led the team that was responsible for the full range of commercial activities including: product development requirements, pricing strategy, market access strategy, salesforce sizing and customer service.
In addition to her oncology experience, Kristine has worked in metabolics, with positions at Genentech and Abbott, and in maternal health (early stage molecular diagnostic company). During her career she has been on five product launch teams with responsibilities for launch planning and KPI tracking.
Prior to her Life Science career, Kristine spent 15 years in commercial positions in high tech.
Kristine has a PhD from the University of Chicago and has completed the Executive Program in Strategy and Organization from the Stanford Graduate School of Business. She is also an active member of Women in Bio.
Gary leads Health Advances’ Hong Kong office and is focused on growing the firm’s practice in the Asia Pacific with pharma, biotech, medtech, and private equity firms.
Gary brings over three decades of healthcare experience in general management (Aventis, Chiron, and Biosite) and mergers and acquisitions (Alere and Becton Dickinson) in the Asia Pacific region. He has expert knowledge in the fields of oncology and cardiovascular medicine in pharma, and point of care expertise in diagnostics. During his fourteen years at Novartis, he managed the global launch of one of the leading medicines in the oncology portfolio.
While at BD, Gary identified over fifty acquisition, licensing, and partnership targets in China, Japan, Southeast Asia, and India and led the integration of Carefusion in the Greater Asia region.
Immediately prior to joining Health Advances, Gary was a Partner/Managing Director at Stout Bluepeak Asia where he worked in portfolio planning, mergers & acquisitions, and capital raising for both regional multinational firms start-up firms in Asia.
He has lived and worked professionally in Japan, Hong Kong, Singapore, and Switzerland.
Gary received his BA with honors in Psychology and Biology from Brown University and his MS in Health Policy and Management from Harvard University.
Holger joined Health Advances in 2019. He is part of Health Advances’ biopharma practice. Holger applies his deep expertise in commercializing scientific innovations in product development strategy, product positioning, and field force optimization across a wide range of technologies, including digital-, cell- and gene therapies.
He is equally versed in life-cycle management and end-of-exclusivity transitions.
Immediately prior to joining Health Advances, Holger held Chief Commercial Officer positions at Biognosys AG, a leading mass spectrometry CRO with focus on proteome discoveries and Cell Medica, a cell therapy company, where Holger was responsible to launch one of the first cell therapy therapeutics into European markets. Holger also held the Chief Operating Officer position at Spiden an early stage medical device company using state-of-the-art detection technologies for vital medical indicator tracking. He previously worked in several senior commercial- and business development roles at Novartis Pharma, both at the global- and local affiliate level, while supporting development-stage and in-market projects across a wide area of therapeutic areas. Earlier, at Bain & Company, Holger consulted for leading pharmaceutical and Private Equity clients primarily on Due Diligences, M&A transitions, and post-merger integrations.
Holger earned his MS degree in Chemistry from the Leibniz University and his PhD from the Swiss Federal Institute of Technology. He earned the CFA designation from the CFA Institute.
Arushi Agarwal joined the Health Advances team in 2011 and spends the majority of her time working in the Diagnostics and Life Sciences Practice. Her work focuses on global commercialization strategies for Precision Medicine diagnostics.
Arushi’s specific areas of focus include companion diagnostics and liquid biopsy testing in oncology, as well as the intersection of Health IT solutions and diagnostic testing.
Prior to joining Health Advances, Arushi received her Masters in Biomedical Engineering from Columbia University where her research focused on the use of microfluidic technologies for regenerative medicine applications. She received a Bachelors in Biology from the Massachusetts Institute of Technology.
Jeff co-leads the Digital Health and Health IT Practice at Health Advances. His 15-year career in healthcare spans digital health and therapeutics, medtech, biopharma, and healthcare services. He holds extensive expertise related to commercialization, global market access, product development, and evidence generation.
Prior to joining Health Advances, Jeff held executive roles in market access, trade, and commercial functions at Akili Interactive, an industry leading digital therapeutics company. During his time at Akil Interactive, Jeff focused on payer strategy, reimbursement, pricing, strategic partnerships, evidence generation, distribution, launch planning and execution.
In addition to his work at Akili, he has served as a Digital Therapeutics task group co-lead for the National Council of Prescription Drug Programs and a Scientific Leadership Board Member for the Digital Medicine Society.
Prior to his time at Akili Interactive, Jeff served as Senior Director for the Medicines Company in their Value Development department. He supported commercialization and global launch of novel drug device combo and the development of additional perioperative and cardiovascular products. Prior to The Medicines Company, Jeff served as a consultant for GfK working in global market access and commercialization. His work spanned numerous therapeutic areas across drug, devices, and diagnostics.
Jeff holds a Master of Science in Physical Therapy and an MBA with a specialization in Health Sector Management from Boston University.
Daniela is a leader in our diagnostics and life sciences tools practice with expertise in opportunity assessment, global commercialization strategy, market access, and business model evaluation. Daniela’s diverse experience in the diagnostics and life sciences tools space provides a strong base to help generate actionable growth strategies for clients.
Prior to joining Health Advances, Daniela helped clients in the healthcare industry optimize their value proposition and global market access strategies to enable product adoption.
Daniela earned her PhD in Chemistry, summa cum laude, from the University of Basel, Switzerland and her MBA from Johnson Graduate School of Management at Cornell University.
Mike joined Health Advances in 2010 and is a leader in our biopharma practice. His areas of expertise include neurology, nephrology and hepatology therapeutics and pharma services, including CROs and CDMOs.
His work includes growth strategy, business development (including partnering, licensing and M&A strategy), commercial due diligence, and product and portfolio optimization. Mike also has robust experience with quantitative analysis, including complex market models, system economics, product forecasting and P&L models.
Prior to joining Health Advances, Mike was an investment banker focused on specialty pharmaceuticals and diagnostics at Thomas Weisel Partners, Stanford Financial Group, and Inverness Advisors. Mike received his Bachelor’s in Biology and Economics from Williams College.
Ned joined Health Advances in 2012 and is a leader in the biopharma practice. He has extensive experience supporting the advancement of novel therapeutics, including efforts focused on development and commercialization strategy, opportunity assessment, portfolio prioritization, competitive market evaluation, and forecasting.
He is a co-leader of the Cell and Gene Therapy practice and a leader of the internal Oncology Business Development Committee. His work spans therapeutic areas, with specific areas of focus including solid tumor oncology, hematologic malignancies, orphan/genetic diseases, CNS, and autoimmune diseases.
Prior to joining Health Advances, Ned was an analyst in the Autoimmune and Inflammatory disease group at Decision Resources, where he was responsible for developing market forecasts and evaluating the competitive landscapes in indications including asthma, COPD, systemic lupus erythematosus, benign prostatic hyperplasia, and rheumatoid arthritis. Ned received his BA in Chemistry from Williams College and his PhD in Chemistry from Johns Hopkins University.
Over the past 25 years, Chris has worked closely with leading companies across the diagnostics and biopharma industries on a broad array of strategy issues. He brings diverse insights from his experience to help leaders make tough decisions in the face of uncertainty.
Prior to joining Health Advances, Chris served as a Director in Global Strategic Marketing in the Rapid Diagnostics Division of Abbott Laboratories.
Chris’s work focuses developing strategies and identifying moves that create sustainable value. This work spans deal diligence, creating foresight, driving innovation and portfolio strategy, and supporting upstream strategic marketing decisions about where to play and how to win.
Prior to Abbott, Chris spent 15 years in management consulting, primarily with Arthur D. Little as a Principal in their Healthcare and Strategy Practices. Chris also served as a Director in Strategy Development at Pharmacia (now Pfizer) and was an Equity Analyst at Prudential covering the specialty pharmaceuticals sector. Chris began his career at Abbott with roles in Core Lab Diagnostics (ADD) and Corporate Finance.
Chris holds a BBA degree from the University of Iowa and an MBA from the Booth School of Business at the University of Chicago.
Kelly is a seasoned leader at Health Advances with expertise in global commercial and market access strategy.Kelly’s diverse experience across our Biopharma project types enables her to craft best-in-class methodologies and ensure innovative answers to our clients’ most critical questions. She collaborates with the Biopharma leadership team on practice strategy, marketing, and business development operations.
Kelly has strong background in several therapeutic areas, including CNS and rare diseases, and is a leader of Health Advances’ internal group dedicated to Global Market Access and Pricing. She spent several years in Zug, Switzerland, providing leadership to grow our European office.
Previously, Kelly worked at Genentech, developing the launch strategy for a novel therapeutic and leading cross-functional brand planning. Prior to this, Kelly conducted academic research in neurology.
Kelly received a BA in Neuroscience and Anthropology from Dartmouth College and has formal training in primary market research techniques, international HTA and reimbursement, and business analytics with certificates from RIVA Market Research and Training Institute, Harvard Business School, ISPOR, Aix-Marseille Université, and University of Sheffield.
Tom heads Health Advances’ Advanced Analytics practice, extracting greater insight from data to answer clients’ most challenging business questions. His experience spans the analytics value chain, from predictive modeling and data science to data warehousing and data engineering. Tom uses his broad experience to advise on the feasibility of various analytical techniques and the relative value and tradeoffs of different types of source data.
Tom has helped many companies build their data strategies, including fit-for-purpose data architectures and data science teams. He advises on analytic techniques, forecasting models, simulations, and champion/challenger strategies. Tom’s background in consumer psychology and market research makes him a versatile partner for a wide range of projects.
Prior to joining Health Advances, Tom served as the Director of Advanced Analytics at L.E.K. Consulting and at Boston Scientific. Prior to that, he held various analytics leadership roles at both consulting and industry firms.
Tom received his BS in Consumer Psychology and MS in Economic Psychology at the University of Tilburg in the Netherlands. He also completed a Post-doc at MIT in System Dynamics. Tom has published a book on Big Data, as well as many papers in peer reviewed journals.
Marcus joined Health Advances in 2022. He has over 15 years’ experience in life sciences strategy, commercialization and investing gained in management consulting, the biopharma industry, and investment banking.
Prior to joining Health Advances, he worked as a senior sell-side equity research analyst at UBS Investment Bank, covering European drug and biotech stocks and authoring several widely read thematic research papers on health policy, pharmaceutical market access, pricing and reimbursement for investors. Previously, Marcus held strategic planning, product management and medical affairs strategy leadership roles at Amgen’s international, Swiss, and European organizations, implementing planning and commercial excellence, managing inline and pipeline products and defining the European patient engagement strategy, respectively. He began his career as management consultant and project leader at Bain & Company and Booz & Company, focusing on pharma and healthcare strategy development. His therapeutic area expertise spans onco-hematology, nephrology, osteology, immunology, dermatology, anti-infectives, CNS, and rare diseases.
Marcus is a licensed pharmacist and earned his PhD at Max Planck Institute of Molecular Physiology/TU Dortmund. He completed a university diploma program in healthcare market access at Aix-Marseille University and is a CFA charterholder.
Masha Dumanis joined Health Advances in 2011 and co-leads the musculoskeletal (MSK) practice area. Masha is a recognized expert in a range of musculoskeletal technologies and a trusted advisor to clients in a range of industries, having supported over 100+ client engagements as a strategy leader. She is also a member of the MedTech senior leadership team and an expert in the burgeoning Women’s Digital Health space.
Masha has deep expertise across all aspects of the MSK care continuum and with MSK products and markets, including pain management, regenerative medicine, traditional implants for joint, extremity, trauma, and spine applications, robotics, AR and VR, digital tools, and instruments.
Masha supports clients with commercialization strategies, buy/sell-side due diligence, reimbursement and market access strategies, business model assessments, competitive and opportunity assessments, growth strategies, and more.
Prior to joining Health Advances, Masha worked at Adnexus Therapeutics (a BMS R&D company) in the Protein Sciences Group. Masha earned a BA in Human Evolutionary Biology from Harvard College; she has also completed additional business coursework through Harvard Business School Online.
Juan leads our US Pricing and Access biopharma practice, helping companies develop pricing strategies from early development to commercialization. Juan has experience across multiple therapeutic areas including oncology, immunology, cardiovascular, infectious diseases, pulmonary conditions, rare disease, and cell and gene therapies.
Juan has developed a unique approach to quantifying price potential for innovative products, taking into consideration a changing policy environment, relative value, and negotiations strategy across payer channels
Prior to joining Health Advances, Juan worked as the Head of Market Access and Pricing at emerging biotechnology companies in the Boston area, and as a Senior Director of Global Market Access at Abbvie. In his early career, Juan was a managing consultant at various healthcare strategy consulting firms including ZS Associates, Navigant, and IQVIA.
Juan earned a Bachelor of Arts in International Relations and Economics from the University of Pennsylvania with distinction, and an MBA in Finance and International Business from the NYU Stern School of Business.
Mark has been advising senior medtech executives for nearly 40 years. He co-founded Health Advances in 1992 after gaining ten years of strategy consulting experience in the healthcare industry as a Partner at Bain & Company, an international management consulting firm.
At Health Advances, Mark is an advisor to clients evaluating the commercial potential and developing go-to-market strategies for new medical devices and service businesses. He also offers expertise in mergers and acquisitions work for strategic and financial buyers, having now supported over $85 billion in client transactions. He serves on the Board of Advisors at Dartmouth’s Geisel School of Medicine, is a Member of the Partners Healthcare System Corporation and an Entrepreneur in Residence at the Harvard Business School. Mark served on the Board of Directors of MassMEDIC for six years and he continues to be a strong advocate for the industry through his frequent speaking engagements and publications.
Mark graduated magna cum laude from Dartmouth College with a degree in engineering and was elected Phi Beta Kappa. He earned his MBA from the Stanford Graduate School of Business where he was honored as an Arjay Miller Scholar.
Paula co-founded Health Advances over 25 years ago, and now advises senior level client engagements focused on strategies to evaluate and optimize the value of developmental and marketed products and services, business units and companies in the healthcare arena.
She is a frequent advisor for Comparative Effectiveness and Pricing/Reimbursement/Market Access projects for clients, as well as developing overall growth strategies for companies and new products in development.
Paula has worked with clients of all sizes across the device, therapeutics, diagnostics, health IT, and services sectors, as well as with investors and non-profit organizations participating in these sectors. She brings strong quantitative skills to bear on projects, while applying her 32+ years of strategy, project management and client advisory skills to ensure insightful and actionable results. Paula has also played a leading role in designing and helping to build Health Advances’ Knowledge Management function and process. This includes the development of proprietary databases and analytic tools, as well as the codification of external and internal healthcare resources and knowledge, which enable the firm to provide the most insightful, data-driven and efficient insights on all of its projects.
Paula started her strategy consulting career at Bain & Company where she led engagements across a range of industries, including healthcare, with a particular focus on technology-driven businesses, manufacturing, and international ventures. Prior to business school, she served as a Tuberculosis (TB) Control worker with the US Peace Corps in South Korea, followed by work with Samsung Shipbuilding and the Atlantic Richfield Northern Light Project at Daewoo Shipbuilding Company, also in South Korea.
Paula graduated from Dartmouth College with honors in International Government. She received her MBA from Columbia University, where she earned Beta Gamma Sigma honors and was an International Fellow.